Dapagliflozin in patients with COVID-19: truth or dare

Rosselló, Xavier; Caimari, Francisca

doi:10.1016/s2213-8587(21)00206-0

Cited by 3 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, further research was initiated to evaluate the effects of dapagliflozin on respiratory failure in patients with COVID-19 (DARE-19) as a multi-center trial (ClinicalTrials.gov identifier: NCT04350593). In this context, Rossello et al reported the safe and effective use of SGLT2 inhibitors in hospitalized patients with cardiometabolic risk factors during the COVID-19 pandemic without any significant efficacy in the acute infection phase in the DARE-19 trial [77]. However, the drug was well-tolerated and the observed data revealed no concerns about volume depletion, increased risk of diabetic ketoacidosis (DKA), or acute kidney injury [78].…”

Section: Anti-inflammatory and Beneficial Systemic Effectsmentioning

confidence: 99%

SGLT2 Inhibitors in Long COVID Syndrome: Is There a Potential Role?

Zimmermann,

Sourij,

Aberer

et al. 2023

JCDD

View full text Add to dashboard Cite

The coronavirus disease (COVID)-19 has turned into a pandemic causing a global public health crisis. While acute COVID-19 mainly affects the respiratory system and can cause acute respiratory distress syndrome, an association with persistent inflammatory stress affecting different organ systems has been elucidated in long COVID syndrome (LCS). Increased severity and mortality rates have been reported due to cardiophysiological and metabolic systemic disorders as well as multiorgan failure in COVID-19, additionally accompanied by chronic dyspnea and fatigue in LCS. Hence, novel therapies have been tested to improve the outcomes of LCS of which one potential candidate might be sodium–glucose cotransporter 2 (SGLT2) inhibitors. The aim of this narrative review was to discuss rationales for investigating SGLT2 inhibitor therapy in people suffering from LCS. In this regard, we discuss their potential positive effects—next to the well described “cardio-renal-metabolic” conditions—with a focus on potential anti-inflammatory and beneficial systemic effects in LCS. However, potential beneficial as well as potential disadvantageous effects of SGLT2 inhibitors on the prevalence and long-term outcomes of COVID-19 will need to be established in ongoing research.

show abstract

Section: Anti-inflammatory and Beneficial Systemic Effectsmentioning

confidence: 99%

SGLT2 Inhibitors in Long COVID Syndrome: Is There a Potential Role?

Zimmermann,

Sourij,

Aberer

et al. 2023

JCDD

View full text Add to dashboard Cite

show abstract

“…Also important is a trend towards better outcomes with dapagliflozin. Given that the total number of primary outcome events was lower than expected, and there was a statistically nonsignificant 20% reduction in the primary outcome in the group receiving dapagliflozin, some experts advocated this study was underpowered [63,65,66]. The RECOV-ERY group announced a larger trial with empagliflozin to further evaluate the hypothesis that SGLT2i can be of benefit in this setting [67].…”

Section: Non-insulin Medicationsmentioning

confidence: 99%

Hospital management of hyperglycemia in the context of COVID-19: evidence-based clinical considerations

Mendes

Souza

Halpern

2022

Diabetol Metab Syndr

View full text Add to dashboard Cite

The COVID-19 pandemic led to an unprecedented crisis, and early on, it has been shown that diabetes is an important risk factor for complications and mortality in infected patients, as demonstrated by several studies. Moreover, hyperglycemia, regardless of whether patients have diabetes, is associated with poorer outcomes, which suggests that adequate monitoring and treatment of elevated glycemia in the hospital setting can improve patient outcomes. In patients with COVID-19, glycemic control may be impaired as a consequence of the infection itself (aggravating pre-existing diabetes and potentially precipitating new-onset diabetes), inflammation, or corticosteroid use—a well-established therapy to reduce COVID-19 complications, especially in the intensive care unit. This article reviews the link between diabetes and hyperglycemia, and COVID-19, with a brief review of potential mechanisms, along with emerging evidence on the effect of glycemic control on COVID-19 outcomes, especially in hospital settings.

show abstract

“…First, dapagliflozin was well tolerated and can be safely used in patients with cardiometabolic risk factors who were hospitalized with COVID-19 pneumonia, regardless of their diabetes status. Second, although findings of dapagliflozin failed to show efficacy in the COVID-19 acute setting, SGLT2i have a promising future not only in patients with diabetes but also in patients with chronic cardiovascular disease or chronic kidney disease, and perhaps even in asymptomatic people [43].…”

Section: Future Perspectives In the Treatment Of Hf For Patients With...mentioning

confidence: 99%

Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review

2022

View full text Add to dashboard Cite

Morbidity and mortality associated with heart failure (HF) has remained high despite advances in therapy. Furthermore, HF-associated risk in patients with type 2 diabetes mellitus (T2D) is even higher than in patients without T2D owing to the strong reciprocal relationship between conditions. However, until recently, no therapy to treat patients with diabetes also reduced cardiovascular risks related to HF. Recent clinical studies (DAPA-HF, EMPEROR-Reduced and EMPEROR-Preserved, SOLOIST-WHF trial) and meta-analysis have demonstrated that sodium-glucose cotransporter-2 inhibitors (SGLT2i) are among the first antidiabetic drugs capable of reducing cardiovascular risks related to HF and improving the prognosis of patients with and without diabetes. Their pleiotropic mechanisms of action place them at the intersection of hemodynamic, metabolic, Elı ´as Delgado, Esteban Jo ´dar, Pedro Mezquita-Raya, and O ´scar Moreno-Pe ´rez have equally participated in the development of the manuscript.

show abstract

Dapagliflozin in patients with COVID-19: truth or dare

Cited by 3 publications

References 9 publications

SGLT2 Inhibitors in Long COVID Syndrome: Is There a Potential Role?

SGLT2 Inhibitors in Long COVID Syndrome: Is There a Potential Role?

Hospital management of hyperglycemia in the context of COVID-19: evidence-based clinical considerations

Benefits of SGLT2i for the Treatment of Heart Failure Irrespective of Diabetes Diagnosis: A State-of-the-Art Review

Contact Info

Product

Resources

About